CollPlant Biotechnologies Ltd.

NasdaqGM:CLGN Stock Report

Market Cap: US$50.0m

CollPlant Biotechnologies Management

Management criteria checks 3/4

CollPlant Biotechnologies' CEO is Yehiel Tal, appointed in Jan 2010, has a tenure of 2.67 years. total yearly compensation is $1.08M, comprised of 50.3% salary and 49.7% bonuses, including company stock and options. directly owns 0.27% of the company’s shares, worth $135.99K. The average tenure of the management team and the board of directors is 8.4 years and 4.9 years respectively.

Key information

Yehiel Tal

Chief executive officer

US$1.1m

Total compensation

CEO salary percentage50.3%
CEO tenure15yrs
CEO ownership0.3%
Management average tenure8.4yrs
Board average tenure4.9yrs

Recent management updates

Why We Think Shareholders May Be Considering Bumping Up CollPlant Biotechnologies Ltd.'s (NASDAQ:CLGN) CEO Compensation

Jul 29
Why We Think Shareholders May Be Considering Bumping Up CollPlant Biotechnologies Ltd.'s (NASDAQ:CLGN) CEO Compensation

Recent updates

We're Interested To See How CollPlant Biotechnologies (NASDAQ:CLGN) Uses Its Cash Hoard To Grow

Aug 20
We're Interested To See How CollPlant Biotechnologies (NASDAQ:CLGN) Uses Its Cash Hoard To Grow

We're Interested To See How CollPlant Biotechnologies (NASDAQ:CLGN) Uses Its Cash Hoard To Grow

Feb 03
We're Interested To See How CollPlant Biotechnologies (NASDAQ:CLGN) Uses Its Cash Hoard To Grow

Is CollPlant Biotechnologies (NASDAQ:CLGN) In A Good Position To Deliver On Growth Plans?

Nov 02
Is CollPlant Biotechnologies (NASDAQ:CLGN) In A Good Position To Deliver On Growth Plans?

CollPlant Biotechnologies Ltd.'s (NASDAQ:CLGN) Shares Lagging The Industry But So Is The Business

Sep 06
CollPlant Biotechnologies Ltd.'s (NASDAQ:CLGN) Shares Lagging The Industry But So Is The Business

Here's Why We're Watching CollPlant Biotechnologies' (NASDAQ:CLGN) Cash Burn Situation

Jul 14
Here's Why We're Watching CollPlant Biotechnologies' (NASDAQ:CLGN) Cash Burn Situation

Here's Why We're Not Too Worried About CollPlant Biotechnologies' (NASDAQ:CLGN) Cash Burn Situation

Mar 02
Here's Why We're Not Too Worried About CollPlant Biotechnologies' (NASDAQ:CLGN) Cash Burn Situation

Companies Like CollPlant Biotechnologies (NASDAQ:CLGN) Are In A Position To Invest In Growth

Nov 10
Companies Like CollPlant Biotechnologies (NASDAQ:CLGN) Are In A Position To Invest In Growth

CollPlant Non-GAAP EPS of -$0.36, revenue of $0.07M

Aug 25

We Think CollPlant Biotechnologies (NASDAQ:CLGN) Can Afford To Drive Business Growth

Jul 22
We Think CollPlant Biotechnologies (NASDAQ:CLGN) Can Afford To Drive Business Growth

CollPlant Biotechnologies Ltd. (NASDAQ:CLGN) Second-Quarter Results: Here's What Analysts Are Forecasting For This Year

Aug 22
CollPlant Biotechnologies Ltd. (NASDAQ:CLGN) Second-Quarter Results: Here's What Analysts Are Forecasting For This Year

CollPlant Biotechnologies - A Cheap, Game-Changing Bio-Printing Platform Company

Aug 05

Why We Think Shareholders May Be Considering Bumping Up CollPlant Biotechnologies Ltd.'s (NASDAQ:CLGN) CEO Compensation

Jul 29
Why We Think Shareholders May Be Considering Bumping Up CollPlant Biotechnologies Ltd.'s (NASDAQ:CLGN) CEO Compensation

The Strong Earnings Posted By CollPlant Biotechnologies (NASDAQ:CLGN) Are A Good Indication Of The Strength Of The Business

Jun 09
The Strong Earnings Posted By CollPlant Biotechnologies (NASDAQ:CLGN) Are A Good Indication Of The Strength Of The Business

CEO Compensation Analysis

How has Yehiel Tal's remuneration changed compared to CollPlant Biotechnologies's earnings?
DateTotal CompensationSalaryCompany Earnings
Sep 30 2024n/an/a

-US$17m

Jun 30 2024n/an/a

-US$17m

Mar 31 2024n/an/a

-US$7m

Dec 31 2023US$1mUS$541k

-US$7m

Sep 30 2023n/an/a

-US$7m

Jun 30 2023n/an/a

-US$7m

Mar 31 2023n/an/a

-US$17m

Dec 31 2022US$1mUS$689k

-US$17m

Sep 30 2022n/an/a

-US$16m

Jun 30 2022n/an/a

-US$15m

Mar 31 2022n/an/a

-US$14m

Dec 31 2021US$1mUS$422k

US$237k

Sep 30 2021n/an/a

US$1m

Jun 30 2021n/an/a

US$5m

Mar 31 2021n/an/a

US$6m

Dec 31 2020US$761kUS$391k

-US$6m

Sep 30 2020n/an/a

-US$7m

Jun 30 2020n/an/a

-US$11m

Mar 31 2020n/an/a

-US$11m

Dec 31 2019US$784kUS$395k

-US$11m

Compensation vs Market: Yehiel's total compensation ($USD1.08M) is above average for companies of similar size in the US market ($USD645.47K).

Compensation vs Earnings: Yehiel's compensation has been consistent with company performance over the past year.

CEO

Yehiel Tal (72 yo)

15yrs

Tenure

US$1,076,000

Compensation

Mr. Yehiel Tal has been the Chief Executive Officer of CollPlant Biotechnologies Ltd. (formerly known as CollPlant Holdings Ltd.) since January 2010 and also serves as its Director since May 2022. Mr. Tal...

Leadership Team

NamePositionTenureCompensationOwnership
Yehiel Tal
CEO & Director15yrsUS$1.08m0.27%
$ 136.0k
Eran Rotem
Deputy CEO & CFO13yrsUS$748.00kno data
Oren Fahimipoor
Vice President of Operations1.8yrsUS$323.00kno data
Elana Gazal
Vice President of Research & Development2.2yrsUS$379.00kno data
Oded Shoseyov
Founder & Chief Scientist21yrsUS$252.97kno data
Hadas Horowitz
Vice President of Human Resources3.8yrsno datano data

8.4yrs

Average Tenure

52.5yo

Average Age

Experienced Management: CLGN's management team is seasoned and experienced (8.4 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Yehiel Tal
CEO & Director2.7yrsUS$1.08m0.27%
$ 136.0k
Abraham Havron
Independent Director8.7yrsno datano data
Elan Penn
Independent Director7yrsno datano data
Roger Pomerantz
Independent Chairman of the Board4.9yrsno datano data
Hugh Evans
Independent Director3.8yrsno data3.3%
$ 1.6m
Ofer Levy
Member of the Scientific Advisory Board & Member of the Clinical Advisory Boardno datano datano data
Joseph Zarzewsky
Independent Director5.4yrsno datano data
Alisa Lask
Independent Director3.4yrsno datano data
Shay Soker
Member of Advisory Board6.6yrsno datano data
Sachin Shridharani
Member of Advisory Boardless than a yearno datano data

4.9yrs

Average Tenure

67yo

Average Age

Experienced Board: CLGN's board of directors are considered experienced (4.9 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/01/10 23:41
End of Day Share Price 2025/01/10 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

CollPlant Biotechnologies Ltd. is covered by 3 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Jason KolbertD. Boral Capital LLC.
Linda PomeroyEdison Investment Research
Swayampakula RamakanthH.C. Wainwright & Co.